
Capricor Therapeutics (CAPR) Stock Forecast & Price Target
Capricor Therapeutics (CAPR) Analyst Ratings
Bulls say
Capricor Therapeutics Inc. exhibits a strong positive outlook due to the remarkable valuation increase of its deramiocel therapy for DMD cardiomyopathy, rising to $2.30 billion from $794 million, reflecting the therapy's promising clinical trial results. The recent Phase III HOPE-3 data highlights significant improvements in key clinical metrics, including a 1.0 point enhancement in PUL 2.0 and positive trends in Late Gadolinium Enhancement, supporting the efficacy of deramiocel. Furthermore, the strategic partnership with NSPharma is expected to drive substantial net sales and enhance the company’s revenue potential, bolstering its growth prospects in the clinical-stage biotechnology sector.
Bears say
Capricor Therapeutics faces substantial challenges, including the slower-than-expected ramp of its product pipeline, which may lead to the need for additional equity or debt financing on unfavorable terms, thus potentially diluting shareholder value. The company's primary product, deramiocel, carries significant clinical risks related to safety, efficacy, and regulatory approval, raising concerns about its market success and overall revenue generation. Additionally, recent data indicating a steady decline in left ventricular ejection fraction (LVEF) in DMD patients suggests that time is of the essence, as delays in product launch or market penetration may limit the therapeutic's impact and financial performance.
This aggregate rating is based on analysts' research of Capricor Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Capricor Therapeutics (CAPR) Analyst Forecast & Price Prediction
Start investing in Capricor Therapeutics (CAPR)
Order type
Buy in
Order amount
Est. shares
0 shares